Cargando…

Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study

BACKGROUND: Before embarking on administrative research, validated case ascertainment algorithms must be developed. We aimed at developing algorithms for identifying inflammatory bowel disease (IBD) patients, date of disease onset, and IBD type (Crohn’s disease [CD] vs ulcerative colitis [UC]) in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Mira Y, Leventer-Roberts, Maya, Rosenblum, Joseph, Zigman, Nir, Goren, Iris, Mourad, Vered, Lederman, Natan, Cohen, Nurit, Matz, Eran, Dushnitzky, Doron Z, Borovsky, Nirit, Hoshen, Moshe B, Focht, Gili, Avitzour, Malka, Shachar, Yael, Chowers, Yehuda, Eliakim, Rami, Ben-Horin, Shomron, Odes, Shmuel, Schwartz, Doron, Dotan, Iris, Israeli, Eran, Levi, Zohar, Benchimol, Eric I, Balicer, Ran D, Turner, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995295/
https://www.ncbi.nlm.nih.gov/pubmed/29922093
http://dx.doi.org/10.2147/CLEP.S151339
_version_ 1783330592122732544
author Friedman, Mira Y
Leventer-Roberts, Maya
Rosenblum, Joseph
Zigman, Nir
Goren, Iris
Mourad, Vered
Lederman, Natan
Cohen, Nurit
Matz, Eran
Dushnitzky, Doron Z
Borovsky, Nirit
Hoshen, Moshe B
Focht, Gili
Avitzour, Malka
Shachar, Yael
Chowers, Yehuda
Eliakim, Rami
Ben-Horin, Shomron
Odes, Shmuel
Schwartz, Doron
Dotan, Iris
Israeli, Eran
Levi, Zohar
Benchimol, Eric I
Balicer, Ran D
Turner, Dan
author_facet Friedman, Mira Y
Leventer-Roberts, Maya
Rosenblum, Joseph
Zigman, Nir
Goren, Iris
Mourad, Vered
Lederman, Natan
Cohen, Nurit
Matz, Eran
Dushnitzky, Doron Z
Borovsky, Nirit
Hoshen, Moshe B
Focht, Gili
Avitzour, Malka
Shachar, Yael
Chowers, Yehuda
Eliakim, Rami
Ben-Horin, Shomron
Odes, Shmuel
Schwartz, Doron
Dotan, Iris
Israeli, Eran
Levi, Zohar
Benchimol, Eric I
Balicer, Ran D
Turner, Dan
author_sort Friedman, Mira Y
collection PubMed
description BACKGROUND: Before embarking on administrative research, validated case ascertainment algorithms must be developed. We aimed at developing algorithms for identifying inflammatory bowel disease (IBD) patients, date of disease onset, and IBD type (Crohn’s disease [CD] vs ulcerative colitis [UC]) in the databases of the four Israeli Health Maintenance Organizations (HMOs) covering 98% of the population. METHODS: Algorithms were developed on 5,131 IBD patients and 2,072 controls, following independent chart review (60% CD and 39% UC). We reviewed 942 different combinations of clinical parameters aided by mathematical modeling. The algorithms were validated on an independent cohort of 160,000 random subjects. RESULTS: The combination of the following variables achieved the highest diagnostic accuracy: IBD-related codes, alone if more than five to six codes or combined with purchases of IBD-related medications (at least three purchases or ≥3 months from the first to last purchase) (sensitivity 89%, specificity 99%, positive predictive value [PPV] 92%, negative predictive value [NPV] 99%). A look-back period of 2–5 years (depending on the HMO) without IBD-related codes or medications best determined the date of diagnosis (sensitivity 83%, specificity 68%, PPV 82%, NPV 70%). IBD type was determined by the majority of CD/UC codes of the three recent contacts or the most recent when less than three contacts were recorded (sensitivity 92%, specificity 97%, PPV 97%, NPV 92%). Applying these algorithms, a total of 38,291 IBD patients were residing in Israel, corresponding to a prevalence rate of 459/100,000 (0.46%). CONCLUSION: The application of the validated algorithms to Israel’s administrative databases will now create a large and accurate ongoing population-based cohort of IBD patients for future administrative studies.
format Online
Article
Text
id pubmed-5995295
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59952952018-06-19 Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study Friedman, Mira Y Leventer-Roberts, Maya Rosenblum, Joseph Zigman, Nir Goren, Iris Mourad, Vered Lederman, Natan Cohen, Nurit Matz, Eran Dushnitzky, Doron Z Borovsky, Nirit Hoshen, Moshe B Focht, Gili Avitzour, Malka Shachar, Yael Chowers, Yehuda Eliakim, Rami Ben-Horin, Shomron Odes, Shmuel Schwartz, Doron Dotan, Iris Israeli, Eran Levi, Zohar Benchimol, Eric I Balicer, Ran D Turner, Dan Clin Epidemiol Original Research BACKGROUND: Before embarking on administrative research, validated case ascertainment algorithms must be developed. We aimed at developing algorithms for identifying inflammatory bowel disease (IBD) patients, date of disease onset, and IBD type (Crohn’s disease [CD] vs ulcerative colitis [UC]) in the databases of the four Israeli Health Maintenance Organizations (HMOs) covering 98% of the population. METHODS: Algorithms were developed on 5,131 IBD patients and 2,072 controls, following independent chart review (60% CD and 39% UC). We reviewed 942 different combinations of clinical parameters aided by mathematical modeling. The algorithms were validated on an independent cohort of 160,000 random subjects. RESULTS: The combination of the following variables achieved the highest diagnostic accuracy: IBD-related codes, alone if more than five to six codes or combined with purchases of IBD-related medications (at least three purchases or ≥3 months from the first to last purchase) (sensitivity 89%, specificity 99%, positive predictive value [PPV] 92%, negative predictive value [NPV] 99%). A look-back period of 2–5 years (depending on the HMO) without IBD-related codes or medications best determined the date of diagnosis (sensitivity 83%, specificity 68%, PPV 82%, NPV 70%). IBD type was determined by the majority of CD/UC codes of the three recent contacts or the most recent when less than three contacts were recorded (sensitivity 92%, specificity 97%, PPV 97%, NPV 92%). Applying these algorithms, a total of 38,291 IBD patients were residing in Israel, corresponding to a prevalence rate of 459/100,000 (0.46%). CONCLUSION: The application of the validated algorithms to Israel’s administrative databases will now create a large and accurate ongoing population-based cohort of IBD patients for future administrative studies. Dove Medical Press 2018-06-07 /pmc/articles/PMC5995295/ /pubmed/29922093 http://dx.doi.org/10.2147/CLEP.S151339 Text en © 2018 Friedman et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Friedman, Mira Y
Leventer-Roberts, Maya
Rosenblum, Joseph
Zigman, Nir
Goren, Iris
Mourad, Vered
Lederman, Natan
Cohen, Nurit
Matz, Eran
Dushnitzky, Doron Z
Borovsky, Nirit
Hoshen, Moshe B
Focht, Gili
Avitzour, Malka
Shachar, Yael
Chowers, Yehuda
Eliakim, Rami
Ben-Horin, Shomron
Odes, Shmuel
Schwartz, Doron
Dotan, Iris
Israeli, Eran
Levi, Zohar
Benchimol, Eric I
Balicer, Ran D
Turner, Dan
Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study
title Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study
title_full Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study
title_fullStr Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study
title_full_unstemmed Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study
title_short Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study
title_sort development and validation of novel algorithms to identify patients with inflammatory bowel diseases in israel: an epi-iirn group study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995295/
https://www.ncbi.nlm.nih.gov/pubmed/29922093
http://dx.doi.org/10.2147/CLEP.S151339
work_keys_str_mv AT friedmanmiray developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT leventerrobertsmaya developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT rosenblumjoseph developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT zigmannir developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT goreniris developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT mouradvered developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT ledermannatan developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT cohennurit developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT matzeran developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT dushnitzkydoronz developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT borovskynirit developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT hoshenmosheb developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT fochtgili developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT avitzourmalka developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT shacharyael developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT chowersyehuda developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT eliakimrami developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT benhorinshomron developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT odesshmuel developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT schwartzdoron developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT dotaniris developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT israelieran developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT levizohar developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT benchimolerici developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT balicerrand developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy
AT turnerdan developmentandvalidationofnovelalgorithmstoidentifypatientswithinflammatoryboweldiseasesinisraelanepiiirngroupstudy